Biosimilar Interchangeability: A Blessing Or A Curse?
As Industry Awaits First FDA Decision, Views Are Mixed On Interchangeability
Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.
